Capnia Revenue and Competitors
Estimated Revenue & Valuation
- Capnia's estimated annual revenue is currently $5.3M per year.
- Capnia's estimated revenue per employee is $251,000
Employee Data
- Capnia has 21 Employees.
- Capnia grew their employee count by 5% last year.
Capnia's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Research Scientist | Reveal Email/Phone |
2 | Associate Engineer | Reveal Email/Phone |
Capnia Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Capnia?
Capnia is a leading provider and developer of innovative healthcare products to be used for the screening, detection and treatment of medical conditions. The Company's flagship products are based on its proprietary technologies, which utilize precision metering of gas flow. Capnia currently markets Serenz® Allergy Relief in the UK and Ireland. The CoSense® End-Tidal Carbon Monoxide (ETCO) Monitor, which measures ETCO that can be used in the detection of hemolysis, and the Infant Solutions product line, including innovative pulmonary resuscitation devices for neonates and infants, are marketed globally. The Company is also clinically evaluating its nasal, non-inhaled CO2 technology to treat trigeminally-mediated pain conditions such as cluster headache and trigeminal neuralgia. For more information, please visit www.capnia.com.  Â
keywords:N/AN/A
Total Funding
21
Number of Employees
$5.3M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.1M | 21 | N/A | N/A |
#2 | $3.7M | 21 | -45% | N/A |
#3 | $2.1M | 21 | N/A | N/A |
#4 | $2.1M | 21 | -22% | N/A |
#5 | $2.1M | 21 | 75% | N/A |